NCT02253992 2020-10-05An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's LymphomaBristol-Myers SquibbPhase 1/2 Terminated232 enrolled 17 charts